Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.
What happened
FDA inspected Similasan AG's facility at Chriesiweg 6, Jonen, from March 27 to April 4, 2023, and reviewed its response to FDA's inspection findings (Form 483), June 2023 information, and website. FDA found the website directs U.S. consumers to retailers selling Similasan ophthalmic products that are unapproved new drugs, and found CGMP violations including media fills that did not simulate commercial aseptic operations, no 100% visual inspection for visible particles, incomplete sterility-testing records, and inadequate quality-unit oversight.
What FDA found
The ophthalmic products are unapproved new drugs because they are not generally recognized as safe and effective and have no FDA-approved application.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The firm's written procedures for media fills (sterility process simulations) did not accurately simulate commercial aseptic manufacturing, including the number of manual interventions.
21 CFR 211.113(b)The firm did not conduct 100% visual inspection of ophthalmic products for visible particles and relied only on acceptable-quality-limit sampling.
21 CFR 211.160(b)Laboratory records did not include complete data, such as negative controls for sterility testing not documented when performed.
21 CFR 211.194(a)The quality unit lacked adequate oversight and written procedures to ensure sterile manufacturing, laboratory controls, complete records, and harmless components.
21 CFR 211.22(a) and 211.22(d)
What FDA wants
FDA tells Similasan to correct the violations promptly and to notify FDA in writing within 15 working days of the steps taken and supporting documents. FDA also recommends a qualified CGMP consultant and may re-inspect before approving new applications listing the firm.
Who should pay attention
- U.S. retailers selling Similasan eye products
- brands that buy sterile ophthalmic drugs from contract manufacturers
- buyers of glycerin or sorbitol components for drugs
This is a summary. Read the original letter on fda.gov.